CGBIO's "DCLASSY PDRN" Receives IND Approval from Ministry of Food and Drug Safety
CGBIO announced on April 17 that its polynucleotide (PDRN)-based skin booster, "DCLASSY PDRN," has received Investigational New Drug (IND) approval from the Ministry of Food and Drug Safety and will begin clinical trials to secure an indication for improving wrinkles around the eyes.
This clinical trial is scheduled to begin at the end of May this year and will target a total of 366 adult men and women aged between 19 and 65. The trial will involve administering DCLASSY PDRN to the wrinkles on both sides of the eyes and evaluating its safety and efficacy.
DCLASSY PDRN is a next-generation PDRN skin booster developed by CGBIO, focusing on resolving issues previously identified with existing PDRN products such as injection pain, immediate post-procedure embossing, and concerns about nodules.
Designed with high-purity, low-viscosity PDRN, it enables smoother injection and even distribution within the skin, while reducing the burden of returning to daily activities immediately after the procedure. The company expects that DCLASSY PDRN will be suitable not only for delicate and sensitive areas like the skin around the eyes but also for patients requiring repeated treatments.
Following the launch of its CaHA-based collagen booster "DCLASSY CaHA" last year, CGBIO is strengthening its skin booster lineup by adding this PDRN product to its portfolio. Through this effort, the company aims to enhance its competitiveness as a provider of customized solutions in the aesthetics market.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Hyun Seung Yoo, CEO of CGBIO, stated, "DCLASSY PDRN is a next-generation skin booster designed to maximize skin regeneration effects while minimizing pain and discomfort after the procedure. Through this clinical trial, we intend to prove its safety and efficacy, and we plan to pursue both domestic and global market launches, targeting a release in 2027."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.